Safety and Efficacy of Prolonged Use of Dalbavancin in Bone and Joint Infections.
bone and joint infections
dalbavancin
osteomyelitis
prosthetic joint infection
Journal
Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
30
10
2018
accepted:
24
02
2019
pubmed:
13
3
2019
medline:
31
3
2020
entrez:
13
3
2019
Statut:
epublish
Résumé
Dalbavancin is a lipoglycopeptide with potent activity against Gram-positive microorganisms, a long half-life, a favorable safety profile, and a high concentration in bone, which makes it an interesting alternative for treatment of osteoarticular infections. We performed a multicentric retrospective study of all patients with an osteoarticular infection (septic arthritis, spondylodiscitis, osteomyelitis, or orthopedic implant-related infection) treated with at least one dose of dalbavancin between 2016 and 2017 in 30 institutions in Spain. In order to evaluate the response, patients with or without an orthopedic implant were separated. A total of 64 patients were included.
Identifiants
pubmed: 30858217
pii: AAC.02280-18
doi: 10.1128/AAC.02280-18
pmc: PMC6496098
pii:
doi:
Substances chimiques
Teicoplanin
61036-62-2
dalbavancin
808UI9MS5K
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2019 American Society for Microbiology.
Références
Clin Microbiol Infect. 2016 Aug;22(8):732.e1-8
pubmed: 27181408
N Engl J Med. 2004 Oct 14;351(16):1645-54
pubmed: 15483283
JBJS Case Connect. 2018 Jan-Mar;8(1):e8
pubmed: 29443819
Clin Infect Dis. 2013 Jan;56(2):182-94
pubmed: 22942204
Clin Infect Dis. 2011 Aug;53(4):334-40
pubmed: 21810745
Cell Microbiol. 2016 Oct;18(10):1405-14
pubmed: 26918656
Antimicrob Agents Chemother. 2009 Mar;53(3):1260-3
pubmed: 19124664
Antimicrob Agents Chemother. 2009 Oct;53(10):4069-79
pubmed: 19596875
Antimicrob Agents Chemother. 2016 Apr 22;60(5):2941-8
pubmed: 26926634
Enferm Infecc Microbiol Clin. 2017 Mar;35(3):189-195
pubmed: 28215487
Antimicrob Agents Chemother. 2010 Jan;54(1):88-92
pubmed: 19841148
Int J Antimicrob Agents. 2009 Apr;33(4):379-82
pubmed: 19097864
Trials. 2015 Dec 21;16:583
pubmed: 26690812
Antimicrob Agents Chemother. 2015 Apr;59(4):1849-55
pubmed: 25561338
J Bone Joint Surg Am. 2008 Aug;90(8):1751-8
pubmed: 18676908
Drugs. 2008;68(5):639-48; discussion 649-51
pubmed: 18370443
Antimicrob Agents Chemother. 2001 Nov;45(11):3238-41
pubmed: 11600390
Clin Infect Dis. 2018 Aug 16;67(5):795-798
pubmed: 29659732
Diagn Microbiol Infect Dis. 2016 Aug;85(4):449-51
pubmed: 27241369
Diagn Microbiol Infect Dis. 2018 Jan;90(1):58-63
pubmed: 29195766
J Clin Pharmacol. 2011 Feb;51(2):229-36
pubmed: 20371736
Clin Infect Dis. 2015 Sep 15;61(6):e26-46
pubmed: 26229122
J Antimicrob Chemother. 2016 May;71(5):1395-401
pubmed: 26929270
Clin Infect Dis. 2016 Dec 15;63(12):1599-1604
pubmed: 27682068
Antimicrob Agents Chemother. 2018 Feb 23;62(3):
pubmed: 29263077
Clin Infect Dis. 2013 Jan;56(1):e1-e25
pubmed: 23223583
Int J Antimicrob Agents. 2018 Apr;51(4):571-577
pubmed: 29180276